Swan A, DeVita M, Michelis M, Anderson R, Preuss H
Effects of chromium supplementation in hemodialysis patients
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Sep) 7:1465 1996
Many chronic dialysis patients have insulin resistance and this resistance
may be partially
responsible for the high levels of atherosclerosis-related morbidity and
mortality in this
population. In other patient populations, chromium supplementation enhances
insulin sensitivity. In
this pilot study, six chronic hemodialysis patients underwent a randomized,
double-blinded
placebo-controlled cross-over study or chromium polynicotinate (200 ucg po
tid) versus placebo, with
each period lasting six weeks.
No changes between placebo and treatment groups were noted regarding body
weight, blood pressure,
baseline glucose, C peptide levels, cholesterol, triglycerides and serum
potassium levels. There
was, however, a significant lowering of circulating insulin levels and 2 hour
glucose levels (after
glucose challenge) in the chromium polynicotinate group.
Comment: The results suggest that chromium supplementation can
therefore favorably influence
glucose/insulin metabolism in chronic hemodialysis patients.
(Michael V. Rocco, M.D., Bowman Gray School of Medicine)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
CRF by organ system :
Nutrition